Oruka Therapeutics

We’re excited to present new preclinical data on ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F, at the AAD Annual Meeting in Orlando. The data show that ORKA-002 has a >3-fold longer half-life in NHPs than bimekizumab, while binding to a nearly identical epitope with similar potency. We expect to initiate a Phase 1 study of ORKA-002 in Q3 2025. For more information, you can read the full news release here: https://lnkd.in/eZV9F4gw, and view the poster on our website here: https://lnkd.in/ewHG6ACg.

Today, we reported Q4 and full-year 2024 financial results and updates from across our pipeline. We made tremendous progress in our first year as a company, including our successful public debut and advancing ORKA-001 into the clinic. Looking forward, we expect to deliver a clinical catalyst every six months, which could progressively establish ORKA-001 and ORKA-002 as the best treatment options in psoriatic disease. Read more here: https://lnkd.in/eRR3eexy

We're looking forward to attending the TD Cowen Health Care Conference tomorrow, where our CEO,?Lawrence Klein, will share our progress in developing novel biologics for psoriasis and other related diseases. Register for the webcast of our presentation here:?https://lnkd.in/eFHHAPTp

Today?marks one year since we formed Oruka. It's just the beginning of our journey, but we're thrilled with our progress so far.?For the occasion, we're sharing a new slide from our corporate deck that recaps our first year and outlines the exciting path ahead.

We’re excited to announce that?the first participants have been dosed in a Phase 1 trial of ORKA-001, our novel, half-life extended monoclonal antibody targeting IL-23p19. Our CMO,?Joana Goncalves, shares more about this significant milestone below. Read the full press release here: https://lnkd.in/gWnr2zdS.

We're thrilled to attend the Jefferies London Healthcare Conference this week, where our CEO, Lawrence Klein, will speak about our progress in developing novel biologics for psoriasis and other related diseases. Register for the webcast of our presentation on November 20 here: https://lnkd.in/e5wH7ted.

October 29 is #WorldPsoriasisDay. This year’s theme of “Family” highlights the impact of psoriatic disease on over 100 million people worldwide as well as their loved ones. Psoriasis presents unique challenges not only for those affected but also for their families. At Oruka, we’re dedicated to developing new treatments that aim to ease this burden by offering those living with psoriasis the greatest possible freedom from disease.

We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.

We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.

We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.